How Long Has Mounjaro Been Used for Diabetes, and What Does That History Mean for You?

You've heard Mounjaro is relatively new — here's what that actually means

A common worry that comes up is the idea that Mounjaro is so new that long-term safety is essentially unknown. That concern is understandable, but it rests on a partial picture. The SURPASS clinical programme, which studied tirzepatide specifically in people with type 2 diabetes, ran across multiple large trials completed between 2019 and 2021 before the medicine received regulatory approval. Those trials covered outcomes including blood sugar control, body weight, cardiovascular markers and tolerability across thousands of participants over periods of up to 40 weeks or more. The broader tirzepatide clinical programme (combining the SURPASS diabetes trials and the SURMOUNT weight-management trials) involved over ten thousand participants in total, producing the evidence base that regulators here and elsewhere evaluated before granting licences.

So while Mounjaro is newer than some medicines, it arrived with a notably substantial dataset. The UK licence for the diabetes indication came in 2022, meaning prescribers in this country have now worked with it in everyday clinical practice for several years. That said, post-marketing surveillance is ongoing, the Black Triangle (▼) status means the MHRA continues to collect and review data from real-world use, which is how regulatory confidence is built over time. You can read more about how long Mounjaro's testing programme ran before it reached UK patients.

What the diabetes trial data tells us, and where uncertainty still lives

The SURPASS trials showed consistent improvements in blood-sugar control alongside meaningful reductions in body weight, which made tirzepatide unusual: many diabetes medicines have a broadly neutral effect on weight, and some can cause gain. In SURPASS-2, for instance, tirzepatide outperformed semaglutide on both glycaemic and weight outcomes in adults with type 2 diabetes, a result that drew considerable clinical attention. The NHS medicines page for tirzepatide reflects the established safety profile, listing the known side effects that emerged through this process.

What remains less established is the very long-term picture beyond the trial windows, five, ten, twenty years of continuous use. That isn't a failing unique to Mounjaro; it applies to most medicines approved within the past decade. MHRA monitoring and ongoing real-world studies are the mechanisms designed to fill that gap progressively. The important point for anyone making a personal decision is that the evidence base that exists is substantial by the standards of a recently approved medicine, and it has been scrutinised by regulators whose job is to weigh benefit against risk. If you want a sense of how long you stay on Mounjaro for diabetes, that page sets out what the clinical guidance suggests about treatment duration. If you want a sense of how the clinical use timeline compares to other treatments, tirzepatide's broader use history covers the global picture.

From diabetes medicine to weight-management licence, and what that means in practice

Mounjaro's first UK licence covered type 2 diabetes. The weight-management indication came later, reflecting the emerging data from the SURMOUNT programme showing significant body-weight reductions in people without diabetes. This sequential licensing matters for one practical reason: the diabetes indication and the weight-loss indication are not interchangeable at the prescribing level. A prescriber assessing someone for Mounjaro for weight management is working from a different set of clinical criteria than one prescribing it for blood-sugar control, even though the medicine itself is identical. NICE's recommendation for tirzepatide in weight management (TA1026, published December 2024) sets out specific BMI and comorbidity thresholds that define who qualifies under that licence; you can explore the weight-loss treatment overview for the full picture.

The years of diabetes experience did, however, inform how clinicians approach the side-effect profile in the weight-management setting. The GI effects (nausea, loose stools, reduced appetite, occasional vomiting, particularly around dose increases) were well characterised in the SURPASS programme long before Mounjaro was prescribed for weight management. That means the guidance prescribers give patients about managing those effects, and the dose-titration schedule starting at 2.5mg, was shaped by a body of experience that predates the weight-loss licence. For anyone curious about what to expect and when, the question of how long Mounjaro takes to show results is worth reading alongside this.

Who should be talking to a prescriber before making any decision

However long the medicine has been available, individual suitability is always a clinical question. History of pancreatitis, certain thyroid conditions, pregnancy, breastfeeding, or plans to conceive are all situations where Mounjaro is not appropriate, these aren't provisional caveats, they are firm points in the SmPC. Mounjaro is not licensed for use in under-18s. Women using oral contraceptives should be aware that for the first four weeks of treatment and for four weeks after each dose increase, absorption of the pill may be reduced, and an additional non-oral contraceptive method is recommended. NHS England's guidance on weight-management injections covers the contraception and surgery considerations in full.

For most people, the question of how long Mounjaro has been used is really a question about confidence, is there enough evidence to make a considered decision? The answer, based on the regulatory record, is yes. The MHRA approved it having reviewed the full dataset; the NICE committee reviewed it again before recommending it; and real-world prescribing has accumulated further experience since. What no amount of population data can answer is whether it is right for a specific individual. That is what a consultation is for. If you'd like to understand the full duration of Mounjaro use in diabetes more precisely, the market history page goes into the regulatory timeline in more detail. To talk through whether treatment is appropriate for you, start your free consultation with a GPhC-registered prescriber at nume.